NCT04956224 - Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years | Biotech Hunter

Enrollment

306

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

November 10, 2021

Study Completion Date

November 18, 2022

Conditions

SARS-CoV-2 Virus Infection

Interventions

BIOLOGICAL

VLA2001

"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"

Trial Locations (8)

1050

Southern Clinical Trials Remuera, Auckland

3010

Lakeland Clinical Trials Rotorua, Rotorua

3118

Lakeland Clinical Trials Culloden, Papamoa

3200

Lakeland Clinical Trials Waikato, Hamilton

7011

Southern Clinical Trials Tasman, Nelson

8013

Southern Clinical Trials Christchurch, Christchurch

0626

Southern Clinical Trials Waitemata, Auckland

0600

Southern Clinical Trials Totara, Auckland

All Listed Sponsors

lead

Valneva Austria GmbH

INDUSTRY